WCG is the world's leading strategic partner to sponsors, CROs, institutions, and sites providing agile, knowledge based services that proactively optimize clinical development programs. For more information, visit www.wcgclinical.com.
212 Carnegie Center
Princeton, NJ 08540
Contact: Lauren Ozmore
WIRB-Copernicus Group® (WCG™) introduces WCG SiteReady™, a first-of-its-kind solution aimed at increasing the efficiency and profitability of clinical research for institutions and independent research sites. WCG’s newest offering helps researchers to optimize their performance, gain a competitive edge, and attract more opportunities for externally-funded clinical trials.
How can researchers identify participants’ overall level of suggestibility and then focus on the minimization of this characteristic to solve the issue of suggestibility in clinical trial?
Genetic testing is making it easier to identify patients for clinical trials. However, genetic testing in the context of clinical trials raises raise important ethical issues, including ones related to informed consent and disclosure of results. Genetic counselors can play a crucial role in helping sponsors address these operational and ethical issues, making trials more efficient, more patient-centered and, ultimately, more successful.
Overall, the landscape of patient recruitment and enrollment have become highly specialized and data-driven. They demand a specialized, data-driven approach that nurtures potential participants and delivers bottom-line results, quickly and within budget. Read how an Enrollment Assistant can reduce the site’s workload, accelerate enrollment and make the entire recruitment process more efficient.
The WIRB-Copernicus Group’s (WCG) Clinical Services Division has acquired the Velos eResearch business line. Velos is a leading provider of clinical trial management solutions (CTMS) that increase the productivity and efficiency of clinical research.
IN 2018 there were many changes, trends, regulations and priorities that shaped the direction of the clinical research and drug development fields. In this paper, WCG experts share what they anticipate in 2019, and what everyone should be prepared for as we approach another year of change.
Insights into the impact that the shutdown will have on the FDA and on the review of investigational products, including those reviews which were already in process at the time of the shutdown.
As you evaluate clinical trial enrollment acceleration strategies, be sure to understand the root causes of slow enrollment and the reasons why traditional acceleration programs do not work.
Study start-up delays have perplexed the best minds in the clinical trials industry for decades. Discover how advanced analytics and an intense focus on the four problem areas can help.
Patient engagement solutions to expedite study recruitment.
A breakdown of regulatory guidances and a clear picture of what the IRB needs to see.
Solutions to manage an overwhelming response to a media campaign.
Five characteristics to look for when finding the best-fit site for your study.
WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, recently announced the opening of the company’s new office in Tokyo, Japan.
WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced its acquisition of ACI Clinical, the top provider of Endpoint Adjudication and Data Monitoring Safety Committees.
What are the things that high-performing clinical research sites do that make sponsors return to them again and again?
Insights on how to avoid startup delays, issues executing the clinical trial, or problems with making payments to sites.
How to bring efficiency back to the review process and to ensure that investigators are spending their time where it matters most, with the study participants.
Although there are clear benefits with the first pill to include a digital sensor that tracks if and when it has been ingested brings, there are also questions regarding patient privacy and choice.
Improving outcomes in clinical trials and reducing the trend toward high placebo response across different therapeutic areas requires the involvement of multiple stakeholders.